Form 483

Noble Life Sciences, Inc Form 483, 2022-07-08

FDA issued a Form 483 to Noble Life Sciences, Inc on 2022-07-08 with 3 public-safe observations.

483· Form 483 issuedBiologics3 observations

Noble Life Sciences, Inc · Sykesville, United States · Issued July 8, 2022

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

8 Jul 2022
21 CFR 58.185(a)(9)

Final report: circumstances affecting data qual., integrity

Cited by Hugh M Mcclure

8 Jul 2022
21 CFR 58.35(b)(5)

QAU: authorize deviations from protocols or SOPs

Cited by Hugh M Mcclure

8 Jul 2022
21 CFR 58.63(a)

Equipment: calibration

Cited by Hugh M Mcclure

Inspected site

NLNoble Life Sciences, IncSykesville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 58.185(a)(9)Cited across public-safe Form 483 observations1x
21 CFR 58.35(b)(5)Cited across public-safe Form 483 observations1x
21 CFR 58.63(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 3 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere